Although SH3PXD2A-AS1’s impact on DDP-resistant NSCLC has not been identified before; however, research indicates that resistance to DDP commonly develops in cancer patients undergoing DDP-based chemotherapy, but the sensitivity to DDP can be regained by regulating specific genes or protein modifications [25–27]. The gene discussed is SH3PXD2A; the disease is cancer.